Design Therapeutics, Inc. (DSGN)Healthcare | Biotechnology | Carlsbad, United States | NasdaqGS
13.86 USD
-1.34
(-8.789%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 13.86 |
Hot Take ↕ | July 11, 2026, 6:15 a.m. EDT
The investment case for Design Therapeutics is currently broken by a catastrophic multi-year decline. Despite the company's promising clinical data in Friedreich's Ataxia and a fortress-like balance sheet with minimal debt, the market has punished the stock relentlessly, erasing nearly 80% of its value over the last four years. This trajectory, characterized by four consecutive years of negative annual returns, suggests the market views the current valuation as insufficient to offset the risks of R&D failure or execution delays, regardless of the strong cash position. The recent price action shows a fragile attempt to stabilize near the 50-day average, but the overwhelming options flow—specifically the heavy put open interest—confirms that traders are betting on further weakness. With no dividend to provide income and a history of steep declines, this is not a value trap; it is a business facing existential uncertainty where the odds of a full recovery remain low. Investors should avoid this security until the multi-year downtrend shows definitive signs of reversal. |
| Model | MAE |
|---|---|
| MSTL_48 ✓ | 0.110702 |
| MSTL_48_105 | 0.117827 |
| AutoARIMA | 0.122422 |
| AutoETS | 0.122422 |
| MSTL | 0.123015 |
| AutoTheta | 0.124522 |
| MSTL_105 | 0.133661 |
Forecast horizon: 60 days | Selected: MSTL_48
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 1.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.117 |
| Excess Kurtosis | -1.24 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.254 |
| Market Cap | 865,341,376 |
| Forward P/E | -8.47 |
| Beta | 1.59 |
| Website | https://www.designtx.com |
As of July 11, 2026, 6:15 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 10, 13, 14) compared to negligible call volume. While there is some speculative call activity at deep strikes (1.0) and far-dated OTM levels (25.0, 30.0), the dominant flow indicates a fear of further collapse rather than a belief in a near-term recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.7975 |
| Address1 | 6,005 Hidden Valley Road |
| Address2 | Suite 110 |
| All Time High | 43.0 |
| All Time Low | 1.94 |
| Ask | 17.6 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,300,760 |
| Average Daily Volume3 Month | 974,029 |
| Average Volume | 974,029 |
| Average Volume10Days | 1,300,760 |
| Beta | 1.59 |
| Bid | 10.78 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 3.492 |
| City | Carlsbad |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.855 |
| Current Ratio | 22.282 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 15.2 |
| Day Low | 13.58 |
| Debt To Equity | 1.254 |
| Display Name | Design Therapeutics |
| Earnings Timestamp | 1,777,406,400 |
| Earnings Timestamp End | 1,777,406,400 |
| Earnings Timestamp Start | 1,777,406,400 |
| Ebitda | -77,735,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.301 |
| Enterprise Value | 645,252,352 |
| Eps Current Year | -1.36 |
| Eps Forward | -1.63571 |
| Eps Trailing Twelve Months | -1.2 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.8078 |
| Fifty Day Average Change | 1.0471992 |
| Fifty Day Average Change Percent | 0.08176261 |
| Fifty Two Week Change Percent | 279.75 |
| Fifty Two Week High | 17.25 |
| Fifty Two Week High Change | -3.3950005 |
| Fifty Two Week High Change Percent | -0.19681162 |
| Fifty Two Week Low | 3.76 |
| Fifty Two Week Low Change | 10.094999 |
| Fifty Two Week Low Change Percent | 2.6848402 |
| Fifty Two Week Range | 3.76 - 17.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,617,024,600,000 |
| Float Shares | 32,871,105 |
| Forward Eps | -1.63571 |
| Forward P E | -8.470327 |
| Free Cashflow | -31,555,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 54 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -58,131,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.31931 |
| Held Percent Institutions | 0.62095 |
| Implied Shares Outstanding | 62,456,974 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-03-26 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California. |
| Long Name | Design Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 865,341,376 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_625814292 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -69,713,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 948,721,435 |
| Number Of Analyst Opinions | 6 |
| Open | 14.96 |
| Operating Cashflow | -54,000,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 858 293 4900 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 13.855 |
| Post Market Time | 1,783,981,117 |
| Previous Close | 15.19 |
| Price Eps Current Year | -10.1875 |
| Price Hint | 2 |
| Price To Book | 3.9676402 |
| Profit Margins | 0.0 |
| Quick Ratio | 22.046 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -1.335 |
| Regular Market Change Percent | -8.78868 |
| Regular Market Day High | 15.2 |
| Regular Market Day Low | 13.58 |
| Regular Market Day Range | 13.58 - 15.2 |
| Regular Market Open | 14.96 |
| Regular Market Previous Close | 15.19 |
| Regular Market Price | 13.855 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 654,557 |
| Return On Assets | -0.20932 |
| Return On Equity | -0.31263 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 62,456,974 |
| Shares Percent Shares Out | 0.0915 |
| Shares Short | 5,715,760 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,876,597 |
| Short Name | Design Therapeutics, Inc. |
| Short Percent Of Float | 0.121300004 |
| Short Ratio | 6.17 |
| Source Interval | 15 |
| State | CA |
| Symbol | DSGN |
| Target High Price | 22.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 21.0 |
| Target Median Price | 21.0 |
| Total Cash | 222,823,008 |
| Total Cash Per Share | 3.568 |
| Total Debt | 2,734,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.183425 |
| Two Hundred Day Average Change | 3.6715746 |
| Two Hundred Day Average Change Percent | 0.36054417 |
| Type Disp | Equity |
| Volume | 654,557 |
| Website | https://www.designtx.com |
| Zip | 92,011 |